comparemela.com

Latest Breaking News On - Incannex healthcare ltd - Page 5 : comparemela.com

The morning catch up: ASX set to rise ahead of August RBA decision; US economy shows signs of strengthening

ASX Futures are pointing to a 25-point or 0.3% rise in early trading this morning, ahead of the RBA’s August interest rate rise decision, scheduled to be.

United-states
Norway
Dallas
Texas
China
United-kingdom
Japan
Australia
Norwegian
Aussie
America
Australian

FIVE at FIVE AU: Cash rate on hold as RBA continues to assess impact of record rate increases

FIVE at FIVE AU: Cash rate on hold as RBA continues to assess impact of record rate increases
proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.

Utah
United-states
Australia
Springdale
New-south-wales
Spargoville
Western-australia
Wattle-dam
Phil-lowe
Simon-linge
Anneke-thompson
Anson-resources-ltd

Incannex Healthcare connects superannuation shareholders with independent advice amid US redomiciliation

Ahead of its intended transition to the Nasdaq, Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) is offering shareholders the chance to engage with an.

Australia
United-states
July-incannex
Joel-latham
Nasdaq
Nasdaq-incannex-healthcare-ltd
Incannex-healthcare-ltd

Incannex thrilled with positive pre-IND meeting for arthritis treatment

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief scientific officer Dr Mark Bleackley tells Proactive the company has completed a constructive.

Mark-bleackley
Incannex-healthcare-ltd
Nasdaq
Drug-administration
Investigational-new-drug

Incannex welcomes valuable feedback from FDA on IND designation for IHL-675A rheumatoid arthritis treatment

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has completed a constructive pre-Investigational New Drug (IND) application meeting with the US Food and Drug.

United-states
Mark-bleackley
Drug-administration
Incannex-healthcare-ltd
Nasdaq
Investigational-new-drug
New-drug-application

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.